Allon Gets Japanese Patent Allowance For Two Neuroprotection Technology Platforms

Allon Therapeutics (Allon) has received Japanese patent, covering its two neuroprotection technology platforms. The patent provides protection for the treatment and prevention of a large number of disorders involving learning and memory deficits, such as those in alzheimer’s disease, down syndrome and normal aging.

Reportedly, the Japanese patent covers the combination use of various derivatives of compounds from Allon’s activity-dependent neuroprotective protein (ADNP) and activity-dependent neurotrophic factor (ADNF) platforms.

Allon’s two neuroprotective technology platforms are based on two naturally occurring proteins produced by the brain in response to a range of insults. The platforms are activity-dependent neuroprotective protein (ADNP) and activity-dependent neurotrophic factor (ADNF).

The two platforms are based on different proteins, the drugs from each are unique molecules with different mechanisms of action and distinct commercial opportunities. The clinical-stage drug, Davunetide is based on ADNP, and its therapeutic potential is focused on frontotemporal dementia, alzheimer’s disease, and cognitive impairment in schizophrenia.

The company said that the preclinical stage drug candidate AL-309 is derived from ADNF and is being developed for the treatment of peripheral neuropathies.